|
|
|
|
| LEADER |
01209 a2200181 4500 |
| 008 |
130220b xxu||||| |||| 00| 0 eng d |
| 020 |
|
|
|a 9783527320745
|
| 082 |
|
|
|a 615.7
|
| 245 |
|
|
|a Post-translational modification of protein biopharmaceuticals /
|c Edited by Gary Walsh.
|
| 260 |
|
|
|b Wiley,
|c 2009.
|a Weinheim :
|
| 300 |
|
|
|a xix, 370 p. ;
|c 24 cm.
|
| 505 |
|
|
|a Post-translational modification in the context of therapeutic proteins--Glycosylation--Protein glycosylation--Mammalian cell lines and glycosylation--Antibody glycosylation--Gonadotropins and the importance of glycosylation--Yeast glycosylation and engineering in the context of therapeutic proteins--Insect cell glycosylation patterns in the context of biopharmaceuticals--Getting bacteria to glycosylate--Other modifications--Biopharmaceuticals--C-terminal a-amidation--Disulfide bond formation--Engineering of PTMS--Glycoengineering of erythropoietin--Glycoengineering--Engineering in a PTM.
|
| 650 |
|
|
|a Biopharmaceutics.
|
| 700 |
|
|
|a Walsh, Gary.
|e Editor.
|
| 942 |
|
|
|c BK
|
| 590 |
|
|
|a BOOK SHOP
|
| 999 |
|
|
|c 96332
|d 96332
|
| 952 |
|
|
|0 0
|1 0
|4 0
|6 615_700000000000000_POS
|7 0
|9 96111
|a UL
|b UL
|c ST1
|d 2011-11-29
|g 0.00
|l 0
|o 615.7 POS
|p 86539
|r 2012-10-28
|v 11937.00
|y BK
|